More news
Advanced BioDesign announces 14.3 million euros of additional funding from its main shareholder Xerys Invest
Two months after the start of "ODYSSEY”, the first-in-human clinical trial targeting acute myeloid leukaemia, Advanced BioDesign has signed an agreement with its historical shareholder, Xerys Invest, for a capital injection of 14.3 million euros.
Advanced Biodesign announces the start of the First-In-Human Clinical Trial "ODYSSEY" targeting Acute Myeloid Leukaemia
After receiving an approval from the National Agency for Medicinal Safety and Health Products (ANSM), Advanced BioDesign announces today the enrolment of the first patient in its "ODYSSEY" (NCT05601726) First-In-Human clinical trial in acute myeloid leukemia (AML).